

Selecta Biosciences to Participate in Two Investor Conferences in February

January 31, 2017 8:00 AM ET

WATERTOWN, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- [Selecta Biosciences, Inc.](http://www.selectabio.com) (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that management will be participating in the following investor conferences in February:

- **Canaccord Genuity Rare Disease and BioPharma 1x1 Day:** Meetings take place February 7, 2017 in New York City.
- **6th Annual LEERINK Partners Global Healthcare Conference:** Fireside chat at 9:00 a.m. ET on Thursday, February 16, 2017 in New York City.

A live and archived webcast of the February 16 fireside chat will be available on the Investors & Media section of the Selecta website at www.selectabio.com.

About Selecta Biosciences, Inc.

[Selecta Biosciences, Inc.](http://www.selectabio.com) is a clinical-stage biopharmaceutical company developing targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) technology is a highly flexible nanoparticle platform, capable of incorporating a wide range of antigens and immunomodulators, allowing the SVP-based products to either induce antigen-specific tolerance or activate the immune system.

Selecta's focus and strategy is to leverage its SVP immune modulating platform to develop and commercialize highly differentiated life-sustaining biologic drugs that are uniquely capable of mitigating the formation of anti-drug antibodies (ADAs). Proprietary programs that use SVP-Rapamycin to enhance efficacy and safety of therapy include SEL-212, Selecta's lead Phase 2 clinical program in chronic refractory gout, and two gene therapy programs for genetic metabolic diseases. Tolerance-inducing SVP biological products also have potential applications in the treatment of allergies and autoimmune diseases.

Selecta is also developing SVP products that activate the immune system to prevent and treat cancer, infections and other diseases.

Selecta is based in Watertown, Massachusetts, USA. For more information, please visit <http://selectabio.com>.

Contact Information:
Jason Fredette
Selecta Biosciences, Inc.
617-231-8078
jfredette@selectabio.com



Selecta Biosciences